Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial
Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse event...
Saved in:
| Published in: | The Lancet (British edition) Vol. 377; no. 9762; pp. 312 - 320 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Kidlington
Elsevier Ltd
22.01.2011
Elsevier Elsevier Limited |
| Subjects: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy.
We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16–32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with
ClinicalTrials.gov, number
NCT00797862.
318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI −0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension.
We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended.
Novartis Pharma AG. |
|---|---|
| AbstractList | Background: Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. Methods: We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16-32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862. Findings: 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6 super(.5 mm Hg (95% CI 5) super(.)3 to 7 super(.7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0) super(.)0001). At 24 weeks, when all patients were on combination treatment, the difference was 1 super(.4 mm Hg (95% CI -0) super(.)05 to 2 super(.9; p=0) super(.)059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension. Interpretation: We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended. Funding: Novartis Pharma AG. Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16–32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862. 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI −0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension. We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended. Novartis Pharma AG. Summary Background Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. Methods We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16–32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov , number NCT00797862. Findings 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI −0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension. Interpretation We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended. Funding Novartis Pharma AG. Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy.BACKGROUNDShort-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy.We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16-32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862.METHODSWe did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16-32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862.318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI -0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension.FINDINGS318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI -0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension.We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended.INTERPRETATIONWe believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended.Novartis Pharma AG.FUNDINGNovartis Pharma AG. BACKGROUND: Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. METHODS: We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16–32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862. FINDINGS: 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI −0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension. INTERPRETATION: We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended. FUNDING: Novartis Pharma AG. Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16-32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862. 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6.5 mm Hg (95% CI 5.3 to 7.7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0.0001). At 24 weeks, when all patients were on combination treatment, the difference was 1.4 mm Hg (95% CI -0.05 to 2.9; p=0.059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension. We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended. Novartis Pharma AG. Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy. We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16-32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862. 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6·5 mm Hg (95% CI 5·3 to 7·7) greater reduction in mean systolic blood pressure than the monotherapy groups (p<0·0001). At 24 weeks, when all patients were on combination treatment, the difference was 1·4 mm Hg (95% CI -0·05 to 2·9; p=0·059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension. We believe that routine initial reduction in blood pressure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended. Novartis Pharma AG. |
| Author | MacDonald, Thomas M Brown, Morris J McInnes, Gordon T Papst, Cheraz Cherif Zhang, Jack |
| Author_xml | – sequence: 1 givenname: Morris J surname: Brown fullname: Brown, Morris J email: m.j.brown@cai.cam.ac.uk organization: Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, UK – sequence: 2 givenname: Gordon T surname: McInnes fullname: McInnes, Gordon T organization: British Hypertension Society, London, UK – sequence: 3 givenname: Cheraz Cherif surname: Papst fullname: Papst, Cheraz Cherif organization: Novartis Pharma AG, Basel, Switzerland – sequence: 4 givenname: Jack surname: Zhang fullname: Zhang, Jack organization: Novartis Pharma AG, Basel, Switzerland – sequence: 5 givenname: Thomas M surname: MacDonald fullname: MacDonald, Thomas M organization: British Hypertension Society, London, UK |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23779369$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21236483$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkm1rFDEUhQep2Bf9CWooiFtwNJlJMjOKyrKsL1AQbAv9FjKZ7G66mWRNssL-Jv-kd3bbCgWtnwaG55x7cu85zPacdzrLnhL8mmDC35xhQnHOq5KPCD7hBcZlfvkgOyC0ojmj1eVednCL7GeHMV5hjCnH7FG2X5Ci5LQuD7JfY2vi0gTtkHQdSguNlLTKrHukFtI5bVFrvVrqgGRvfWdWxgHi-9Y4mYwHWQQlMs4kIy1KQcvUa5dQTEEmPd-gmQ9osVnpkLSLg0J5l4K3aDSeTKan0-_j8-nJWyRRgAS-N1F3r9BKBmmttvk8-PUKbMH8cfZwJm3UT66_R9nFp-n55Et--u3z18n4NFecNCknsqGMFpQ1tJWUVERyJQtJS8W6tm0krUrGSV1XqmYFbduO8ErpFrOy5bLjrDzKXu58V8H_WOuYBIRS2lrptF9HUbOS1lVN-P0krYq6qJoSyNE_SchQMwrONaDHd9Arvw4OXgyTedVwUg6Tn11D67bXnVgF08uwETeXBeDFNSAjXHQGy1Um_uHKCmLxBrh3O04FH2PQM6FM2l4W7mesIFgMfRPbvomhTMOvbd_EJajZHfXNgPt0z3e6mfRCzgMkuzgrMGEYk6IpOAXi447QcOmfRgcRldFO6Q7KqpLovLl3xoc7DspCTWEZS73R8XapRMRC4J3J4EHw1mEweP93g_8I8Bu3rB4l |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_S0140_6736_14_61468_9 crossref_primary_10_4997_JRCPE_2011_109 crossref_primary_10_1016_j_jash_2011_08_005 crossref_primary_10_1038_s41371_018_0149_8 crossref_primary_10_1016_j_reval_2025_104583 crossref_primary_10_1161_CIRCRESAHA_118_313294 crossref_primary_10_1007_s40256_023_00625_1 crossref_primary_10_1016_j_cjca_2013_02_020 crossref_primary_10_1136_bmjopen_2015_007645 crossref_primary_10_1016_j_ccl_2016_08_010 crossref_primary_10_1161_JAHA_117_006940 crossref_primary_10_1177_875512251202800104 crossref_primary_10_1177_2040622312446244 crossref_primary_10_26599_1671_5411_2025_01_008 crossref_primary_10_1111_ijcp_12180 crossref_primary_10_1586_erc_11_71 crossref_primary_10_1007_s10557_012_6380_6 crossref_primary_10_1111_1755_5922_12015 crossref_primary_10_1016_j_cjca_2013_02_015 crossref_primary_10_1080_10641963_2020_1723618 crossref_primary_10_1007_s00059_012_3587_z crossref_primary_10_4997_JRCPE_2012_314 crossref_primary_10_1007_s12325_013_0020_9 crossref_primary_10_1016_j_jash_2015_01_012 crossref_primary_10_1097_HJH_0000000000001181 crossref_primary_10_1016_S1889_1837_18_30059_X crossref_primary_10_1007_s40292_013_0022_3 crossref_primary_10_1161_CIRCOUTCOMES_116_003152 crossref_primary_10_2165_11594140_000000000_00000 crossref_primary_10_1016_j_clinthera_2011_11_007 crossref_primary_10_1097_CM9_0000000000002109 crossref_primary_10_1016_S0140_6736_18_30309_X crossref_primary_10_1038_jhh_2012_42 crossref_primary_10_1016_j_ijcard_2012_10_007 crossref_primary_10_1016_j_amjcard_2012_03_034 crossref_primary_10_1093_ndt_gfaa085 crossref_primary_10_1016_j_ceca_2014_02_019 crossref_primary_10_1016_S0140_6736_10_62270_2 crossref_primary_10_3389_fphys_2022_1070115 crossref_primary_10_1097_MNH_0b013e3283495819 crossref_primary_10_1586_erc_11_90 crossref_primary_10_1177_2040622313495288 crossref_primary_10_1080_17512433_2018_1412826 crossref_primary_10_1097_FJC_0b013e31823fc3f5 crossref_primary_10_1177_23969873221100032 crossref_primary_10_1111_j_1582_4934_2012_01632_x crossref_primary_10_1097_MD_0000000000000168 crossref_primary_10_1210_clinem_dgaf081 crossref_primary_10_1016_j_jacc_2018_10_022 crossref_primary_10_1007_s11739_014_1168_2 crossref_primary_10_1016_S0140_6736_11_60594_1 crossref_primary_10_1093_ajh_hpt158 crossref_primary_10_1097_MJT_0b013e31824a0ed7 crossref_primary_10_3390_ijms23010074 crossref_primary_10_1155_2013_627938 crossref_primary_10_1161_JAHA_117_006986 crossref_primary_10_1016_j_jacc_2018_07_008 crossref_primary_10_1371_journal_pone_0070111 crossref_primary_10_17352_2455_2976_000010 crossref_primary_10_1177_23969873231219416 crossref_primary_10_1161_HYPERTENSIONAHA_112_201566 crossref_primary_10_1517_14740338_2011_585966 crossref_primary_10_1038_s41371_021_00557_w crossref_primary_10_1186_s12916_025_03892_8 crossref_primary_10_1111_j_1445_5994_2012_02927_x crossref_primary_10_3390_medicina61040764 crossref_primary_10_1016_j_ahj_2013_10_020 crossref_primary_10_1080_17512433_2018_1509705 crossref_primary_10_1111_j_1751_7176_2011_00552_x crossref_primary_10_1093_bja_aex327 crossref_primary_10_1111_j_1751_7176_2011_00514_x crossref_primary_10_1007_s00210_016_1249_z crossref_primary_10_1517_14740338_2012_696608 crossref_primary_10_1007_s00380_011_0204_7 crossref_primary_10_1093_bib_bbac040 crossref_primary_10_1007_s40292_014_0041_8 crossref_primary_10_1111_j_1751_7176_2011_00437_x crossref_primary_10_1038_srep24697 crossref_primary_10_1016_j_bja_2021_05_006 crossref_primary_10_1016_j_cellsig_2012_04_003 crossref_primary_10_3390_jcm6060061 crossref_primary_10_1185_03007995_2011_637914 crossref_primary_10_1185_03007995_2012_729505 crossref_primary_10_1093_ajh_hpt210 crossref_primary_10_1038_jhh_2016_46 crossref_primary_10_1038_s41598_025_95021_x crossref_primary_10_1111_j_1742_1241_2012_02967_x crossref_primary_10_1016_j_jash_2011_01_002 crossref_primary_10_1016_S0140_6736_11_60593_X crossref_primary_10_1586_erc_12_7 crossref_primary_10_1007_s00508_015_0748_0 crossref_primary_10_1080_17460441_2022_2104247 crossref_primary_10_1161_HYPERTENSIONAHA_112_194167 crossref_primary_10_1093_eurheartj_ehy420 crossref_primary_10_1111_jch_12725 crossref_primary_10_1016_j_ahj_2023_05_019 crossref_primary_10_1038_hr_2012_185 crossref_primary_10_1517_14656566_2012_736492 crossref_primary_10_1016_S0140_6736_17_30331_8 crossref_primary_10_1161_HYPERTENSIONAHA_113_01504 crossref_primary_10_1161_JAHA_117_007760 crossref_primary_10_1002_pds_4884 crossref_primary_10_1016_j_nurpra_2011_08_005 crossref_primary_10_1016_S0140_6736_11_60592_8 crossref_primary_10_1111_j_1751_7176_2011_00483_x crossref_primary_10_1016_j_jash_2011_12_002 |
| Cites_doi | 10.1111/j.1524-6175.2002.2041.x 10.1016/S0140-6736(04)16451-9 10.1161/CIRCULATIONAHA.107.690396 10.1016/S0140-6736(05)67185-1 10.1016/j.clinthera.2007.03.018 10.1001/jama.289.19.2560 10.1001/jama.1979.03290280031022 10.1016/S0002-9149(00)01199-1 10.1016/S0149-2918(07)80079-8 10.1038/sj.jhh.1002140 10.1097/00004872-199506000-00018 10.1016/j.clinthera.2008.04.002 10.1161/CIRCULATIONAHA.108.787630 10.7326/0003-4819-84-6-639 10.1016/j.amjmed.2008.09.038 10.1038/ajh.2010.139 10.1097/01.hjh.0000226210.95936.bc 10.1056/NEJMoa0806182 10.1016/S0140-6736(02)11911-8 10.1016/S0140-6736(02)08089-3 10.1161/HYPERTENSIONAHA.108.123455 10.1136/bmj.b1665 10.1038/jhh.2009.90 10.1038/ng.361 10.1016/S0140-6736(03)14739-3 10.1136/hrt.2006.107706 |
| ContentType | Journal Article |
| Copyright | 2011 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2011 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 22-Jan 28, 2011 |
| Copyright_xml | – notice: 2011 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 22-Jan 28, 2011 |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7S9 L.6 7X8 |
| DOI | 10.1016/S0140-6736(10)62003-X |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials - QC Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database (ProQuest) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE - Academic AGRICOLA ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 320 |
| ExternalDocumentID | 2291302851 21236483 23779369 10_1016_S0140_6736_10_62003_X US201500129264 S014067361062003X 1_s2_0_S014067361062003X |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Novartis Pharma AG. |
| GroupedDBID | --- --K --M .1- .55 .CO .FO .GJ 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3EH 3O- 4.4 41~ 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 8WZ 9JM A6W AABNK AAEDT AAEDW AAEJM AAFWJ AAIKJ AAKAS AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ABWVN ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACUHS ACVFH ADBBV ADCNI ADMUD ADNMO ADXHL ADZCM AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AGQPQ AHHHB AHMBA AHQJS AIGII AIIUN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKVCP AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI ARTTT ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 D0S DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EFKBS EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS EPT ESX EVS EWM EX3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 MVM N9A NAPCQ O-L O9- OD. OO~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ Q~Q R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TEORI TH9 TLN TWZ UAP UBE UHU UKHRP UQL UV1 WOQ WOW WUQ X7M XAX XDU XPP YYM YYQ Z5R ZGI ZMT ZXP ZY4 ~G0 ~HD 3V. 88A AACTN AAYOK ABTAH ACRZS AFCTW AFKWA AJOXV ALIPV AMFUW M0L M41 PKN RIG SDF ABLVK ABYKQ AHPSJ AJBFU NHB XFK Y6R ZA5 AEQTP FBQ 9DU AAYXX AFFHD CITATION AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7S9 L.6 7X8 PUEGO |
| ID | FETCH-LOGICAL-c619t-1a945424594ba4171a6ca2a43c5dbb9a473561887c8524bbd167ceb053b6ad653 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 137 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000286850400028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Sat Sep 27 16:58:56 EDT 2025 Sun Sep 28 06:39:46 EDT 2025 Sun Nov 09 12:51:38 EST 2025 Tue Oct 28 09:44:15 EDT 2025 Mon Jul 21 05:46:00 EDT 2025 Mon Jul 21 09:15:41 EDT 2025 Sat Nov 29 04:00:22 EST 2025 Tue Nov 18 22:37:07 EST 2025 Wed Dec 27 19:05:42 EST 2023 Fri Feb 23 02:18:31 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Oct 14 19:34:52 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9762 |
| Keywords | Antianginal agent Hypertension Enzyme Calcium antagonist Enzyme inhibitor Aliskiren Check Non peptide compound Cardiovascular disease Medicine Peptidases Randomization Renin Treatment Surveillance Amlodipine Hydrolases Antihypertensive agent Clinical trial Strategy Aspartic endopeptidases Dihydropyridine derivatives |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2011 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c619t-1a945424594ba4171a6ca2a43c5dbb9a473561887c8524bbd167ceb053b6ad653 |
| Notes | http://dx.doi.org/10.1016/S0140-6736(10)62003-X ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 21236483 |
| PQID | 856796136 |
| PQPubID | 40246 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_853487816 proquest_miscellaneous_847282793 proquest_miscellaneous_1678548538 proquest_journals_856796136 pubmed_primary_21236483 pascalfrancis_primary_23779369 crossref_citationtrail_10_1016_S0140_6736_10_62003_X crossref_primary_10_1016_S0140_6736_10_62003_X fao_agris_US201500129264 elsevier_sciencedirect_doi_10_1016_S0140_6736_10_62003_X elsevier_clinicalkeyesjournals_1_s2_0_S014067361062003X elsevier_clinicalkey_doi_10_1016_S0140_6736_10_62003_X |
| PublicationCentury | 2000 |
| PublicationDate | 2011-01-22 |
| PublicationDateYYYYMMDD | 2011-01-22 |
| PublicationDate_xml | – month: 01 year: 2011 text: 2011-01-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2011 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Dahlof, Sever, Poulter (bib6) 2005; 366 Wald, Law, Morris, Bestwick, Wald (bib7) 2009; 122 Brown, Dickerson (bib29) 1995; 13 Julius, Kjeldsen, Weber (bib4) 2004; 363 Jamerson, Weber, Bakris (bib17) 2008; 359 Dahlöf, Devereux, Kjeldsen (bib16) 2002; 359 Braun-Dullaeus, Zhang, Hristoskova, Haring, Liao (bib8) 2010; 12 Hood, Taylor, Ashby, Brown (bib27) 2007; 116 Lewington, Clarke, Qizilbash, Peto, Collins (bib21) 2002; 360 Brown (bib26) 2010; 23 Law, Morris, Wald (bib24) 2009; 338 Brown (bib10) 2007; 93 Feldman, Zou, Vandervoort, Wong, Nelson, Feagan (bib12) 2009; 53 Laragh, Letcher, Pickering (bib25) 1979; 241 Chobanian, Bakris, Black (bib2) 2003; 289 Philipp, Smith, Glazer (bib13) 2007; 29 Bakris, Weir (bib23) 2003; 5 (bib15) 2006 Primatesta, Poulter (bib1) 2006; 24 Fogari, Zoppi, Derosa (bib20) 2007; 21 Messerli, Oparil, Feng (bib19) 2000; 86 Newton-Cheh, Johnson, Gateva (bib22) 2009; 41 Zappe, Palmer, Calhoun, Purkayastha, Samuel, Jamerson (bib11) 2010; 24 Mancia, De Backer, Dominiczak (bib3) 2007; 28 Fogari, Malamani, Zoppi (bib18) 2007; 29 Brown (bib9) 2008; 118 Chrysant, Melino, Karki, Lee, Heyrman (bib14) 2008; 30 Kaplan, Kem, Holland, Kramer, Higgins, Gomez-Sanchez (bib28) 1976; 84 Turnbull (bib5) 2003; 362 Dahlof (10.1016/S0140-6736(10)62003-X_bib6) 2005; 366 Chobanian (10.1016/S0140-6736(10)62003-X_bib2) 2003; 289 Hood (10.1016/S0140-6736(10)62003-X_bib27) 2007; 116 Lewington (10.1016/S0140-6736(10)62003-X_bib21) 2002; 360 Laragh (10.1016/S0140-6736(10)62003-X_bib25) 1979; 241 Bakris (10.1016/S0140-6736(10)62003-X_bib23) 2003; 5 Kaplan (10.1016/S0140-6736(10)62003-X_bib28) 1976; 84 Dahlöf (10.1016/S0140-6736(10)62003-X_bib16) 2002; 359 Brown (10.1016/S0140-6736(10)62003-X_bib9) 2008; 118 Law (10.1016/S0140-6736(10)62003-X_bib24) 2009; 338 Braun-Dullaeus (10.1016/S0140-6736(10)62003-X_bib8) 2010; 12 (10.1016/S0140-6736(10)62003-X_bib15) 2006 Messerli (10.1016/S0140-6736(10)62003-X_bib19) 2000; 86 Jamerson (10.1016/S0140-6736(10)62003-X_bib17) 2008; 359 Fogari (10.1016/S0140-6736(10)62003-X_bib20) 2007; 21 Turnbull (10.1016/S0140-6736(10)62003-X_bib5) 2003; 362 Primatesta (10.1016/S0140-6736(10)62003-X_bib1) 2006; 24 Mancia (10.1016/S0140-6736(10)62003-X_bib3) 2007; 28 Brown (10.1016/S0140-6736(10)62003-X_bib26) 2010; 23 Julius (10.1016/S0140-6736(10)62003-X_bib4) 2004; 363 Brown (10.1016/S0140-6736(10)62003-X_bib29) 1995; 13 Brown (10.1016/S0140-6736(10)62003-X_bib10) 2007; 93 Zappe (10.1016/S0140-6736(10)62003-X_bib11) 2010; 24 Wald (10.1016/S0140-6736(10)62003-X_bib7) 2009; 122 Philipp (10.1016/S0140-6736(10)62003-X_bib13) 2007; 29 Chrysant (10.1016/S0140-6736(10)62003-X_bib14) 2008; 30 Feldman (10.1016/S0140-6736(10)62003-X_bib12) 2009; 53 Newton-Cheh (10.1016/S0140-6736(10)62003-X_bib22) 2009; 41 Fogari (10.1016/S0140-6736(10)62003-X_bib18) 2007; 29 21236482 - Lancet. 2011 Jan 22;377(9762):278-9 21494776 - Curr Hypertens Rep. 2011 Aug;13(4):259-61 21856641 - Evid Based Med. 2011 Oct;16(5):148-9 21531262 - Lancet. 2011 Apr 30;377(9776):1491; author reply 1492 21531263 - Lancet. 2011 Apr 30;377(9776):1491; author reply 1492 21531261 - Lancet. 2011 Apr 30;377(9776):1490-1; author reply 1492 |
| References_xml | – volume: 41 start-page: 666 year: 2009 end-page: 676 ident: bib22 article-title: Genome-wide association study identifies eight loci associated with blood pressure publication-title: Nat Genet – volume: 23 start-page: 926 year: 2010 end-page: 928 ident: bib26 article-title: Heterogeneity of blood pressure response to therapy publication-title: Am J Hypertens – volume: 359 start-page: 995 year: 2002 end-page: 1003 ident: bib16 article-title: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol publication-title: Lancet – volume: 24 start-page: 483 year: 2010 end-page: 491 ident: bib11 article-title: Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension publication-title: J Hum Hypertens – volume: 360 start-page: 1903 year: 2002 end-page: 1913 ident: bib21 article-title: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies publication-title: Lancet – volume: 116 start-page: 268 year: 2007 end-page: 275 ident: bib27 article-title: The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio publication-title: Circulation – volume: 12 start-page: A27 year: 2010 ident: bib8 article-title: First-line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension publication-title: J Clin Hypertens – volume: 29 start-page: 563 year: 2007 end-page: 580 ident: bib13 article-title: Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension publication-title: Clin Ther – volume: 363 start-page: 2022 year: 2004 end-page: 2031 ident: bib4 article-title: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial publication-title: Lancet – volume: 5 start-page: 202 year: 2003 end-page: 209 ident: bib23 article-title: Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches publication-title: J Clin Hypertens (Greenwich) – volume: 338 start-page: b1665 year: 2009 ident: bib24 article-title: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies publication-title: BMJ – volume: 28 start-page: 1462 year: 2007 end-page: 1536 ident: bib3 article-title: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) publication-title: Eur Heart J – volume: 24 start-page: 1193 year: 2006 end-page: 1200 ident: bib1 article-title: Improvement in hypertension management in England: results from the Health Survey for England 2003 publication-title: J Hypertens – volume: 241 start-page: 151 year: 1979 end-page: 156 ident: bib25 article-title: Renin profiling for diagnosis and treatment of hypertension publication-title: JAMA – volume: 359 start-page: 2417 year: 2008 end-page: 2428 ident: bib17 article-title: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients publication-title: N Engl J Med – volume: 366 start-page: 895 year: 2005 end-page: 906 ident: bib6 article-title: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial publication-title: Lancet – volume: 122 start-page: 290 year: 2009 end-page: 300 ident: bib7 article-title: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials publication-title: Am J Med – volume: 30 start-page: 587 year: 2008 end-page: 604 ident: bib14 article-title: The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study publication-title: Clin Ther – volume: 93 start-page: 1026 year: 2007 end-page: 1033 ident: bib10 article-title: Renin: friend or foe? publication-title: Heart – volume: 84 start-page: 639 year: 1976 end-page: 645 ident: bib28 article-title: The intravenous furosemide test: a simple way to evaluate renin responsiveness publication-title: Ann Intern Med – volume: 29 start-page: 413 year: 2007 end-page: 418 ident: bib18 article-title: Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study publication-title: Clin Ther – volume: 53 start-page: 646 year: 2009 end-page: 653 ident: bib12 article-title: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial publication-title: Hypertension – volume: 21 start-page: 220 year: 2007 end-page: 224 ident: bib20 article-title: Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients publication-title: J Hum Hypertens – volume: 13 start-page: 701 year: 1995 end-page: 707 ident: bib29 article-title: Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension publication-title: J Hypertens – volume: 362 start-page: 1527 year: 2003 end-page: 1535 ident: bib5 article-title: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials publication-title: Lancet – year: 2006 ident: bib15 publication-title: Hypertension: management of hypertension in adults in primary care (NICE clinical guideline 34) – volume: 86 start-page: 1182 year: 2000 end-page: 1187 ident: bib19 article-title: Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension publication-title: Am J Cardiol – volume: 118 start-page: 773 year: 2008 end-page: 784 ident: bib9 article-title: Aliskiren publication-title: Circulation – volume: 289 start-page: 2560 year: 2003 end-page: 2572 ident: bib2 article-title: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report publication-title: JAMA – volume: 5 start-page: 202 year: 2003 ident: 10.1016/S0140-6736(10)62003-X_bib23 article-title: Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/j.1524-6175.2002.2041.x – volume: 12 start-page: A27 issue: suppl 1 year: 2010 ident: 10.1016/S0140-6736(10)62003-X_bib8 article-title: First-line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension publication-title: J Clin Hypertens – volume: 28 start-page: 1462 year: 2007 ident: 10.1016/S0140-6736(10)62003-X_bib3 article-title: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) publication-title: Eur Heart J – volume: 363 start-page: 2022 year: 2004 ident: 10.1016/S0140-6736(10)62003-X_bib4 article-title: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(04)16451-9 – volume: 116 start-page: 268 year: 2007 ident: 10.1016/S0140-6736(10)62003-X_bib27 article-title: The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.690396 – volume: 366 start-page: 895 year: 2005 ident: 10.1016/S0140-6736(10)62003-X_bib6 publication-title: Lancet doi: 10.1016/S0140-6736(05)67185-1 – volume: 29 start-page: 563 year: 2007 ident: 10.1016/S0140-6736(10)62003-X_bib13 publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.03.018 – volume: 289 start-page: 2560 year: 2003 ident: 10.1016/S0140-6736(10)62003-X_bib2 article-title: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report publication-title: JAMA doi: 10.1001/jama.289.19.2560 – volume: 241 start-page: 151 year: 1979 ident: 10.1016/S0140-6736(10)62003-X_bib25 article-title: Renin profiling for diagnosis and treatment of hypertension publication-title: JAMA doi: 10.1001/jama.1979.03290280031022 – volume: 86 start-page: 1182 year: 2000 ident: 10.1016/S0140-6736(10)62003-X_bib19 article-title: Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension publication-title: Am J Cardiol doi: 10.1016/S0002-9149(00)01199-1 – year: 2006 ident: 10.1016/S0140-6736(10)62003-X_bib15 – volume: 29 start-page: 413 year: 2007 ident: 10.1016/S0140-6736(10)62003-X_bib18 article-title: Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study publication-title: Clin Ther doi: 10.1016/S0149-2918(07)80079-8 – volume: 21 start-page: 220 year: 2007 ident: 10.1016/S0140-6736(10)62003-X_bib20 article-title: Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients publication-title: J Hum Hypertens doi: 10.1038/sj.jhh.1002140 – volume: 13 start-page: 701 year: 1995 ident: 10.1016/S0140-6736(10)62003-X_bib29 article-title: Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension publication-title: J Hypertens doi: 10.1097/00004872-199506000-00018 – volume: 30 start-page: 587 year: 2008 ident: 10.1016/S0140-6736(10)62003-X_bib14 article-title: The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study publication-title: Clin Ther doi: 10.1016/j.clinthera.2008.04.002 – volume: 118 start-page: 773 year: 2008 ident: 10.1016/S0140-6736(10)62003-X_bib9 article-title: Aliskiren publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.787630 – volume: 84 start-page: 639 year: 1976 ident: 10.1016/S0140-6736(10)62003-X_bib28 article-title: The intravenous furosemide test: a simple way to evaluate renin responsiveness publication-title: Ann Intern Med doi: 10.7326/0003-4819-84-6-639 – volume: 122 start-page: 290 year: 2009 ident: 10.1016/S0140-6736(10)62003-X_bib7 article-title: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials publication-title: Am J Med doi: 10.1016/j.amjmed.2008.09.038 – volume: 23 start-page: 926 year: 2010 ident: 10.1016/S0140-6736(10)62003-X_bib26 article-title: Heterogeneity of blood pressure response to therapy publication-title: Am J Hypertens doi: 10.1038/ajh.2010.139 – volume: 24 start-page: 1193 year: 2006 ident: 10.1016/S0140-6736(10)62003-X_bib1 article-title: Improvement in hypertension management in England: results from the Health Survey for England 2003 publication-title: J Hypertens doi: 10.1097/01.hjh.0000226210.95936.bc – volume: 359 start-page: 2417 year: 2008 ident: 10.1016/S0140-6736(10)62003-X_bib17 article-title: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients publication-title: N Engl J Med doi: 10.1056/NEJMoa0806182 – volume: 360 start-page: 1903 year: 2002 ident: 10.1016/S0140-6736(10)62003-X_bib21 article-title: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies publication-title: Lancet doi: 10.1016/S0140-6736(02)11911-8 – volume: 359 start-page: 995 year: 2002 ident: 10.1016/S0140-6736(10)62003-X_bib16 article-title: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol publication-title: Lancet doi: 10.1016/S0140-6736(02)08089-3 – volume: 53 start-page: 646 year: 2009 ident: 10.1016/S0140-6736(10)62003-X_bib12 article-title: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.108.123455 – volume: 338 start-page: b1665 year: 2009 ident: 10.1016/S0140-6736(10)62003-X_bib24 article-title: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies publication-title: BMJ doi: 10.1136/bmj.b1665 – volume: 24 start-page: 483 year: 2010 ident: 10.1016/S0140-6736(10)62003-X_bib11 article-title: Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension publication-title: J Hum Hypertens doi: 10.1038/jhh.2009.90 – volume: 41 start-page: 666 year: 2009 ident: 10.1016/S0140-6736(10)62003-X_bib22 article-title: Genome-wide association study identifies eight loci associated with blood pressure publication-title: Nat Genet doi: 10.1038/ng.361 – volume: 362 start-page: 1527 year: 2003 ident: 10.1016/S0140-6736(10)62003-X_bib5 article-title: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(03)14739-3 – volume: 93 start-page: 1026 year: 2007 ident: 10.1016/S0140-6736(10)62003-X_bib10 article-title: Renin: friend or foe? publication-title: Heart doi: 10.1136/hrt.2006.107706 – reference: 21494776 - Curr Hypertens Rep. 2011 Aug;13(4):259-61 – reference: 21856641 - Evid Based Med. 2011 Oct;16(5):148-9 – reference: 21236482 - Lancet. 2011 Jan 22;377(9762):278-9 – reference: 21531263 - Lancet. 2011 Apr 30;377(9776):1491; author reply 1492 – reference: 21531262 - Lancet. 2011 Apr 30;377(9776):1491; author reply 1492 – reference: 21531261 - Lancet. 2011 Apr 30;377(9776):1490-1; author reply 1492 |
| SSID | ssj0004605 |
| Score | 2.4030292 |
| Snippet | Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether... Summary Background Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early... BACKGROUND: Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We... Background: Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We... |
| SourceID | proquest pubmed pascalfrancis crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 312 |
| SubjectTerms | Amides - therapeutic use Amlodipine - therapeutic use Antihypertensive Agents - therapeutic use Arterial hypertension. Arterial hypotension Biological and medical sciences Blood and lymphatic vessels Blood pressure Calcium Channel Blockers - therapeutic use Calcium channels Cardiology. Vascular system Clinical trials Diastole - drug effects Double-Blind Method Drug therapy Drug Therapy, Combination Edema Female Fumarates - therapeutic use General aspects Humans Hypertension Hypertension - drug therapy Hypotension Internal Medicine Male Medical sciences Middle Aged Mortality patients Systole - drug effects systolic blood pressure therapeutics |
| Title | Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S014067361062003X https://www.clinicalkey.es/playcontent/1-s2.0-S014067361062003X https://dx.doi.org/10.1016/S0140-6736(10)62003-X https://www.ncbi.nlm.nih.gov/pubmed/21236483 https://www.proquest.com/docview/856796136 https://www.proquest.com/docview/1678548538 https://www.proquest.com/docview/847282793 https://www.proquest.com/docview/853487816 |
| Volume | 377 |
| WOSCitedRecordID | wos000286850400028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Source (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Journals (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfohhAvfMPCoDISD5tEttj55gWVqhMPtFRdh_oW2Y4D1dJkNC0SfxP_JHdOmgmp3ZB4OalJfrKdXO_Dd74j5K0CrRwKEduuSh3b82Nmx5HidhZEXGuHS9eVptlEOBpFs1k8bnJzqiatciMTjaBOS4V75KeRjzsezA0-XP2wsWkUBlebDhodso9FElyTuTfedizSZLhfH-A5PW8vHjHnODAZWrNdqqmTiRJzJkUFry2r-13sNkiNYjp7-J9LekQeNBYp7dUs9Jjc0cUTcm_YxNyfkt-9fF5dgmQsqChSCgYjhQmq-XpB8dRwoXMqQSNe6iUVi7xMsRk2PFIuwOc2n52KCpB0jmlKMFCb2k6rujLuLwqGM_0ODvHSpNMDokmgp0e9fn_weTDpTQfH76mg8FbSEjhTp-8oFi3Pc53b5mAKNe1HnpGLs8G0_8luWjzYCjy3lc1E7PkYfI09KTwWMhEowYXnKj-VMhbYGDlgIAhV5HNPypQFodISJIcMRBr47nOyV5SFPiA0xoCtBHOIYa_yDOBZiIVSlZvGUjmBRbzN101UU_8c23DkyZZEN7hkmCKZWeSkhV3VBUBuAwQb1kk2p1tBHiegom4DhtuAumqkSpWwpOKJU6MRDO48QgEZtcjGcKoNon8Z9AC4OxHfQKUkF-ccN8BwbxLsZIt0_2L5dvkci1S6QWyRww1fJ-0cW6a2yJv2LjAGxqFEocs1LAMMJHCUQdVahO54BowmHnEY5oZHfBe87YjBSC_qP-D1DLGmkBe5L2-c4SG5X0cImM35K7K3Wq71a3JX_VzNq2WXdMLJV6Sz0NAIaNRnXbL_cTAaT-DX0KnpFCkfGvrF0HHXSKI_HyZ-pA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMALd1gZDCOBtEmExc4dCaGqdNq0tkKsk_pmbMeFamkymha034T4j5yT24TUbrzsgVfHn-zY52b7XAh5pUErB1JGlqNj23K9iFlRqLk19kNujM2V46ii2EQwGISjUfRpjfyuY2HQrbKWiYWgjjONd-S7oYc3HszxP5x-t7BoFD6u1hU0Sqo4NGc_4cSWvz_4CNv7mvO97rCzb1VFBSwNZ4W5xWTkevjcF7lKuixg0teSS9fRXqxUJLEUr8-A9XTocVepmPmBNgpoVfky9rFIBEj865hWDz0I-_ZwWRhm4VF_HjC0e9Q0bjN7xy88wkarVOG1sczQR1PmsE3jsr7GagO4UIR7d_-zJbxH7lQWN22XLHKfrJn0AbnZr3wKHpJf7WSSn4DkT6lMYwoGMYUF0ZPFlGJUdGoSqkDjn5gZldMki7HYN3TJpmpS3qRSmQOSTtANCwZqXPdpXmb-PaNwMKDf4MA_K8IFAFEFCNDtdqfT7XU_t4fdnXdUUtiFOAPOM_EbiknZk8QkVhF4Q4vyKo_I8ZUs1WOynmap2SA0wgdpBeYew1rsY4CPA0wEq504Utr2W8StqUnoKr87lhlJxBJHPmgqiFCMWuRtAzstE5xcBvBrUhV19C7oGwEq-DJgsAxo8kpq5oKJnAu7RCOY2QUUkGGDrAzD0uD7l0E3gJuE_AoqUxwfcbzgw7tXOAe0yNZfLNb8PscknI4ftchmzUeimWPDRC3ysvkKhIHvbDI12QJ-AwxAzwU7OGwRuqIPGIU85DDMBV08xw2DkMFIT0qGP58h5kxyQ-fphTN8QW7tD_s90TsYHG6S2-VrCLM4f0bW57OFeU5u6B_zST7bKuQYJV-umuv_AHWB0Bc |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1tb9MwELbGQBNfeIeFwTASSJtEaOy8IyFUda2YNqaJbVK_BdtxoFqalKYF9TfxC_h33OVtQmo3vuwDX5M8smPf-c723T2EvFJglX0hQtNWsWU6bsjMMFDcTLyAa21xaduyJJvwj46C4TA8XiO_m1wYDKts1sRyoY5zhWfkncDFEw9me52kjoo43ht8mHw3kUAKL1obNo1KQg704ifs3or3-3sw1a85H_RPex_NmmDAVLBvmJlMhI6LV3-hI4XDfCY8JbhwbOXGUoYCaXk9BmqoApc7UsbM85WWILfSE7GHhBGw-t_0bRBiTFLvsWUpmWV0_UXyUOekfbjDrF2vjA4brjKLNxKRY7ymKGDKkoprY7UzXBrFwd3_eDjvkTu1J067lercJ2s6e0A2PtWxBg_Jr246Ks7BImRUZDEFR5nC4KjRfEwxWzrTKZXgCZzrKRXjNI-RBBw-ycdyVJ2wUlEAko4wPAsaakP6aVFVBF5Q2DDQb4uJnpZpBICoEwfoTrfX6x_2P3dP-7vvqKAwI3EOGqnjNxSLtaepTs0yIYeWtCuPyNm1DNVjsp7lmd4kNMSLagluIEOO9gTgiY8FYpUdh1JZnkGcRrIiVdd9R_qRNFoS4AePSoGMhgZ528ImVeGTqwBeI7ZRk9ULdigC03wV0F8G1EW9mhYRiwoeWRUawcwqoYAMWmTtMFaO4L80ugmaFYmvYEqjsxOOB394Jgv7A4Ns_6Vu7e9zLM5pe6FBthqdito-tgplkJftWxAMvH8Tmc7n8BvgGLoO-MeBQeiKb8BZ5AGHZi75xLWdwA8YtPSkUv6LHmItJSewn17awxdkA5Q9Otw_Otgit6tLEmZy_oysz6Zz_ZzcUj9mo2K6XS5plHy5bqX_A4ck2JU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aliskiren+and+the+calcium+channel+blocker+amlodipine+combination+as+an+initial+treatment+strategy+for+hypertension+control+%28ACCELERATE%29%3A+a+randomised%2C+parallel-group+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Brown%2C+Morris+J&rft.au=McInnes%2C+Gordon+T&rft.au=Papst%2C+Cheraz+Cherif&rft.au=Zhang%2C+Jack&rft.date=2011-01-22&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.volume=377&rft.issue=9762&rft.spage=312&rft.epage=320&rft_id=info:doi/10.1016%2FS0140-6736%2810%2962003-X&rft.externalDocID=S014067361062003X |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673611X60038%2Fcov150h.gif |